Onyema Ogbuagu

Last updated

Onyema Eberechukwu Ogbuagu (born June 20, 1978) is an American-born infectious diseases physician, educator, researcher, and clinical trial investigator, who was raised and educated in Nigeria. He is an associate professor at Yale School of Medicine in New Haven, CT and is the director of the Yale AIDS Program clinical trials unit. [1] His research contributions have focused on HIV/AIDS prevention and COVID-19 vaccination and treatment clinical trials. [2] He switched his focus at the beginning of the 2019 COVID pandemic and participated as a principal investigator (PI) on the Pfizer-BioNtech COVID-19 vaccine trials [3] [4] and the Remdesivir SIMPLE trial [5] in 2020 and 2021. In pursuit of his global health component of his career, Ogbuagu also supports postgraduate physician medical education programs in low and middle income countries in sub-Saharan Africa in Rwanda (2013–2018) and Liberia (2017 to date) as well as HIV treatment programs in Liberia (2018 to date).

Contents

In his role as public health educator, he has worked to increase public understanding of mRNA vaccines. [6] [7] [8] [9] [10] [11] Ogbuagu has also worked to decrease vaccine hesitancy. [12] [13] He has been a co-author on 43 scholarly articles, according to the National Library of Medicine. [14] According to Google Scholar, one article he co-authored on Remdesivir and its use for Covid that appeared in JAMA was cited 504 times. [15] Ogbuagu was selected as the commencement speaker for Yale School of Medicine's class of 2021. [16]

Early life and education

Onyema Ogbuagu and an identical twin brother, Chibuzo Ogbuagu II, were born to Chibuzo and Stella Ogbuagu. Nigerian doctoral students attending Yale University and University of Pennsylvania, respectively, when their twins were born. The couple had graduated in the 1974 from the University of Nigeria, Nsukka, where Stella was valedictorian. [17] The family returned to Nigeria when Onyema and Chibuzo were five years old.

Before their recent retirement, Onyema's father was vice-chancellor of Abia State University, Nigeria, and his mother was a professor of sociology and a former deputy vice-chancellor of the same institution. [18]

Onyema Ogbuagu attended Auntie Margaret International Primary School in Calabar, and obtained his secondary education at Federal Government College, Okigwe, Imo State, Nigeria (1988 to1994), graduating at 15. He graduated from the College of Medical Sciences, University of Calabar, Nigeria in 2014. He completed his medical internship at the Ebonyi State University Teaching Hospital in Abakaliki, Nigeria. He then returned to the United States, where he interned at the Elmhurst campus of Icahn School of Medicine at Mount Sinai. Ogbuagu completed his residency and chief residency at Mount Sinai in 2010. [1]

Ogbuagu completed an infectious diseases fellowship at Yale School of Medicine in 2012 and assumed a faculty position as an assistant professor in the same year. Currently, he is an associate professor of medicine in the Department of Internal Medicine, Section of Infectious Diseases. [19]

Personal life

Ogbuagu is married to Grace Igiraneza Ogbuagu. [20] [21] She is a nephrologist and member of the International Nephrology Society. [22]

Career

Ogbuagu is an HIV/AIDS physician and leads a clinical trials program at Yale that conducts research on infectious diseases. He has been the principal investigator on pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds for HIV in addition to his recent work on COVID-19 vaccinations and therapeutics. [23]

He is a clinician at Yale Medicine, the medical practice of Yale School of Medicine, and sees patients at Yale New Haven Hospital's Nathan Smith Clinic. [24]

Ogbuagu trains physicians in Liberia and Rwanda. He has been a visiting professor to the National University of Rwanda since 2012, where he mentors medical residents and junior faculty and assists them in conducting clinical research projects that have local importance such as HIV/AIDS and antimicrobial resistance. In Liberia, he is program director of Yale's Office of Global Health's efforts to support Internal Medicine residency training. He trained the first infectious disease fellow in Liberia. [25]

COVID-19 and HIV/AIDS research

At the beginning of the COVID-19 pandemic, Ogbuagu shifted his focus from AIDS/HIV research and patient care to lead vaccine trials for COVID-19 at the Yale Center for Clinical Investigation where he was a PI on the Pfizer-BioNtech COVID-19 mRNA vaccine trial arms at Yale in adults as well as the pediatric studies for12-15 year-olds and 6 month to 11 year olds. The adult Pfizer BioNtech vaccine received emergency use authorization in the United States from the Food and Drug Administration (FDA) in 2020 and full FDA approval in 2021. There were approximately 150 sites for the Pfizer BioNtech mRNA trial, each led by a principal investigator.

Ogbuagu was also a PI for the second Phase 2b Sanofi-Glaxo Smith Klein novel COVID-19 vaccination candidate. He was also the Yale site PI for COVID treatment studies including the Remdesivir SIMPLE moderate and Severe trials. [26]

Previous to this clinical trial work, he researched pharmacokinetic, phase 2 and 3 safety and efficacy trials of novel antiviral compounds (HIV), and conducted HIV prevention trials. [1] [27]

Awards

In 2015, Ogbuagu elected as a Fellow of the American College of Physicians. In 2017, He received the Steve Huot Faculty Award for Dedication and Excellence from Yale School of Medicine's  Internal Medicine Primary Care Program.

In 2014 and in 2019, he received the Gerald H. Friedland prize for outstanding international research presentation by the Connecticut Infectious Diseases Society. On February 18, 2020, he also received an award from the Rwanda College of Physicians for his contribution in the fight against infectious diseases.

Publications

Related Research Articles

<span class="mw-page-title-main">Pfizer</span> American multinational pharmaceutical and biotechnology corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer (1824–1906) and his cousin Charles F. Erhart (1821–1891).

<span class="mw-page-title-main">Seroconversion</span> Development of specific antibodies in the blood serum as a result of infection or immunization

In immunology, seroconversion is the development of specific antibodies in the blood serum as a result of infection or immunization, including vaccination. During infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but the antibody is absent. During seroconversion, the antibody is present but not yet detectable. After seroconversion, the antibody is detectable by standard techniques and remains detectable unless the individual seroreverts, in a phenomenon called seroreversion, or loss of antibody detectability, which can occur due to weakening of the immune system or decreasing antibody concentrations over time. Seroconversion refers the production of specific antibodies against specific antigens, meaning that a single infection could cause multiple waves of seroconversion against different antigens. Similarly, a single antigen could cause multiple waves of seroconversion with different classes of antibodies. For example, most antigens prompt seroconversion for the IgM class of antibodies first, and subsequently the IgG class.

Correlates of immunity or correlates of protection to a virus or other infectious pathogen are measurable signs that a person is immune, in the sense of being protected against becoming infected and/or developing disease.

The United States Military HIV Research Program was initiated by the United States Congress in 1986, in reaction to the threat of lost effectiveness of U.S./Allied troops due to HIV infection. The mission of MHRP is to develop an HIV-1 vaccine, provide prevention, care, and treatment, and conduct meaningful HIV/AIDS research for the global community through the President's Emergency Plan for AIDS Relief (PEPFAR). It is centered at the Walter Reed Army Institute of Research (WRAIR), and has established five international research sites in Africa and Asia. MHRP also partners with the Armed Forces Research Institute of Medical Sciences (AFRIMS) in Thailand. MHRP works closely with The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF), most notably in the development of the RV144 HIV vaccine in Thailand. MHRP is the largest research program supported by the HJF.

Kathleen Maletic Neuzil is the Director of the Center for Vaccine Development at the University of Maryland School of Medicine. She was elected to the National Academy of Medicine in 2019.

mRNA vaccine Type of vaccine

An mRNAvaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into immune cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen or by a cancer cell. These protein molecules stimulate an adaptive immune response that teaches the body to identify and destroy the corresponding pathogen or cancer cells. The mRNA is delivered by a co-formulation of the RNA encapsulated in lipid nanoparticles that protect the RNA strands and help their absorption into the cells.

<span class="mw-page-title-main">COVID-19 vaccine</span> Vaccine against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID‑19).

<span class="mw-page-title-main">COVID-19 drug repurposing research</span> Drug repurposing research related to COVID-19

Drug repositioning is the repurposing of an approved drug for the treatment of a different disease or medical condition than that for which it was originally developed. This is one line of scientific research which is being pursued to develop safe and effective COVID-19 treatments. Other research directions include the development of a COVID-19 vaccine and convalescent plasma transfusion.

<span class="mw-page-title-main">COVID-19 drug development</span> Preventative and therapeutic medications for COVID-19 infection

COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19). From early 2020 through 2021, several hundred drug companies, biotechnology firms, university research groups, and health organizations were developing therapeutic candidates for COVID-19 disease in various stages of preclinical or clinical research, with 419 potential COVID-19 drugs in clinical trials, as of April 2021.

<span class="mw-page-title-main">Solidarity trial</span> Accelerated multinational clinical trial program to identify therapies against COVID-19

The Solidarity trial for treatments is a multinational Phase III-IV clinical trial organized by the World Health Organization (WHO) and partners to compare four untested treatments for hospitalized people with severe COVID-19 illness. The trial was announced 18 March 2020, and as of 6 August 2021, 12,000 patients in 30 countries had been recruited to participate in the trial.

Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

<span class="mw-page-title-main">Annie Luetkemeyer</span> American physician and infectious diseases researcher

Annie F. Luetkemeyer is an American physician and researcher who is Professor of Medicine and Infectious Diseases at the University of California, San Francisco. She specializes in infectious diseases, in particular tuberculosis, human immunodeficiency virus and viral hepatitis. During the COVID-19 pandemic Luetkemeyer led a clinical trial of remdesivir. She has also researched treatment of COVID-19 as a co-infection with HIV.

Sarah L. Pett is a Professor of Infectious Diseases at University College London. Pett is interested in the immunopathology of infections and the development of optimised treatment pathways for infections. During the COVID-19 pandemic, Pett led a clinical trial that investigated the efficacy of remdesivir as a treatment for coronavirus disease.

<span class="mw-page-title-main">Jeanne Marrazzo</span> American microbiologist

Jeanne Marisa Marrazzo is an American physician-scientist and infectious diseases specialist. She was the director of the University of Alabama School of Medicine Division of Infectious Diseases and focused on prevention of HIV infection using biomedical interventions. Marrazzo is a fellow of the American College of Physicians and Infectious Disease Society of America. On August 2, 2023 Lawrence A. Tabak, acting director for the National Institutes of Health (NIH), named Jeanne M. Marrazzo as director of NIH’s National Institute of Allergy and Infectious Diseases.

The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those awaiting vaccination, as well as for the estimated millions of immunocompromised persons who are unlikely to respond robustly to vaccination, treatment remains important. Some people may experience persistent symptoms or disability after recovery from the infection, known as long COVID, but there is still limited information on the best management and rehabilitation for this condition.

<span class="mw-page-title-main">Steven Grinspoon</span>

Steven Grinspoon is an American physician who is a Professor of Medicine at Harvard Medical School, Chief of the Massachusetts General Hospital (MGH) Metabolism Unit and Director of the Nutrition Obesity Research Center at Harvard. In addition, he is the MGH Endowed Chair in Neuroendocrinology and Metabolism. His work investigates the neuroendocrine regulation of body composition, and physiologic consequences of fat distribution on cardiovascular disease and inflammation. He has investigated the effects of reduced growth hormone on metabolic dysregulation in obesity and was the first to propose the use of a Growth Hormone-releasing Hormone (GHRH) analogue to increase endogenous GH secretion on lipodystrophy and generalized obesity, which led to the FDA approval of Tesamorelin for excess visceral fat accumulation in HIV-infected patients. This work has now been extended to show effects on non-alcoholic fatty liver disease (NAFLD). More recently, his research focuses on the inflammatory mechanisms by which ectopic fat and other metabolic perturbations contribute to HIV-Cardiovascular disease (CVD), and in this regard, he led the AHA State of the Science Conference on CVD in HIV. Additionally, he is leading the multicenter REPRIEVE study, the first study of a primary prevention strategy for CVD in people living with HIV. He has also investigated increased Renin-Angiotensin-Aldosterone System (RAAS) activation and immune activation in relationship to visceral fat accumulation, and the mechanisms of subcutaneous adipose dysfunction involving DICER. Grinspoon has served on the Harvard faculty since 1995 and has been selected by the American Society for Clinical Investigation and the Association of American Physicians for his scientific contributions. He received the American Federation of Medical Research Investigator of the Year Award in 2005 and the Edward H. Ahrens Jr. Award for Patient Oriented Research in 2014 as well as the Endocrine Society Laureate Award for Translational Research in 2016. He has published over 330 articles and mentored over 40 trainees in his career. He was elected as a Member of the American Clinical and Climatological Association for his achievements in 2017. His work demonstrating the effects of Tesamorelin to reduce hepatic fat and fibrosis progression in NAFLD, published in Lancet HIV, was a finalist for the Clinical Research Forum’s top 10 Clinical Research Achievement Awards in 2020. In 2015, he became the Principal Investigator of the NIH-funded Nutrition Obesity Research Center at Harvard.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

<span class="mw-page-title-main">Nirmatrelvir/ritonavir</span> Antiviral combination medication

Nirmatrelvir/ritonavir, sold under the brand name Paxlovid, is a co-packaged medication used as a treatment for COVID‑19. It contains the antiviral medications nirmatrelvir and ritonavir and was developed by Pfizer. Nirmatrelvir inhibits SARS-CoV-2 main protease, while ritonavir is a strong CYP3A inhibitor, slowing down nirmatrelvir metabolism and therefore boosting its effect. It is taken by mouth.

<span class="mw-page-title-main">David Boulware</span>

David Boulware is a professor of medicine and a practicing infectious disease physician at the University of Minnesota Medical School. He is a member of the graduate faculty for the University of Minnesota School of Public Health Epidemiology PhD program and for the Microbiology, Immunology, and Cancer Biology (MICaB) graduate program. Boulware was the first Lois & Richard King Distinguished Assistant Professorship at the University of Minnesota. Boulware is an active medical researcher engaged in clinical trials in infectious diseases. His expertise is particularly in the realm of HIV-related meningitis, including Cryptococcosis and Tuberculous meningitis.

<span class="mw-page-title-main">Judith Aberg</span> American physician

Judith Aberg is an American physician who is the George Baehr Professor of Clinical Medicine at Mount Sinai Hospital. She was appointed Dean of System Operations for Clinical Sciences at the Icahn School of Medicine at Mount Sinai. Her research considered infectious diseases, including HIV/AIDS and COVID-19.

References

  1. 1 2 3 "Onyema Ogbuagu, MBBCh, FACP, FIDSA". medicine.yale.edu. Retrieved 2021-06-17.
  2. ↑ Sopeyin, Anuoluwapo; Hornsey, Emilio; Okwor, Tochi; Alimi, Yewande; Raji, Tajudeen; Mohammed, Abdulaziz; Moges, Hiwot; Onwuekwe, Ezinne V C.; Minja, Frank J.; Gon, Giorgia; Ogbuagu, Onyema; Ogunsola, Folasade; Paintsil, Elijah (2020). "Transmission risk of respiratory viruses in natural and mechanical ventilation environments: Implications for SARS-CoV-2 transmission in Africa". BMJ Global Health. 5 (8): e003522. doi:10.1136/bmjgh-2020-003522. PMC   7462043 . PMID   32863269.
  3. ↑ Frenck, Robert W.; Klein, Nicola P.; Kitchin, Nicholas; Gurtman, Alejandra; Absalon, Judith; Lockhart, Stephen; Perez, John L.; Walter, Emmanuel B.; Senders, Shelly; Bailey, Ruth; Swanson, Kena A. (2021-07-15). "Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents". The New England Journal of Medicine. 385 (3): 239–250. doi:10.1056/NEJMoa2107456. ISSN   1533-4406. PMC   8174030 . PMID   34043894.
  4. ↑ Polack, Fernando P.; Thomas, Stephen J.; Kitchin, Nicholas; Absalon, Judith; Gurtman, Alejandra; Lockhart, Stephen; Perez, John L.; Pérez Marc, Gonzalo; Moreira, Edson D.; Zerbini, Cristiano; Bailey, Ruth (2020-12-31). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". The New England Journal of Medicine. 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. ISSN   1533-4406. PMC   7745181 . PMID   33301246.
  5. ↑ Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Arribas López, José Ramón; Cattelan, Anna Maria; Soriano Viladomiu, Alex; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA. 324 (11): 1048–1057. doi:10.1001/jama.2020.16349. hdl:1887/3185309. ISSN   0098-7484. PMC   7442954 . PMID   32821939.
  6. ↑ Julia Hollingsworth, Adam Renton, Emma Reynolds, Nada Bashir, Melissa Macaya and Meg Wagner (2020-12-10). "Pfizer principal investigator "very optimistic" about positive news after FDA meeting". CNN. Retrieved 2021-06-17.{{cite web}}: CS1 maint: multiple names: authors list (link)
  7. ↑ "Video: What you need to know about COVID-19 vaccine distribution". ABC News. Retrieved 2021-06-17.
  8. ↑ "Low public trust could hurt vaccine distribution in minority communities". MSNBC.com. Retrieved 2021-06-17.
  9. ↑ New Pfizer trial shows vaccine 100% effective in teens 12-15 , retrieved 2021-06-17
  10. ↑ Johnson, Carolyn Y. (27 August 2020). "Large U.S. covid-19 vaccine trials are halfway enrolled, but lag on participant diversity". Washington Post. Retrieved 2021-06-17.
  11. ↑ "Connecticut's Shot in the Arm: State leaders, health officials discuss COVID-19 vaccine". WTNH.com. 2020-12-02. Retrieved 2021-08-30.
  12. ↑ "T.D. Jakes Hosts Conversation with COVID-19 Vaccine Scientists". www.prnewswire.com (Press release). Retrieved 2021-06-17.
  13. ↑ "COVID Vaccines and the Return to Life: Part 1". The Aspen Institute. Retrieved 2021-07-02.
  14. ↑ "Onyema Ogbuagu - Search Results - PubMed". PubMed. Retrieved 2021-06-23.
  15. ↑ Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Arribas López, José Ramón; Cattelan, Anna Maria; Soriano Viladomiu, Alex; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA. 324 (11): 1048–1057. doi:10.1001/jama.2020.16349. hdl:1887/3185309. ISSN   0098-7484. PMC   7442954 . PMID   32821939.
  16. ↑ "MD Class of 2021 Selects Associate Professor Onyema Ogbuagu as Commencement Speaker". medicine.yale.edu. Retrieved 2021-06-17.
  17. ↑ "Meet Onyema Ogbuagu, di Nigerian inside Pfizer Covid-19 vaccine breakthrough". BBC News Pidgin. Retrieved 2021-06-17.
  18. ↑ "PROFILE: Meet Onyema Ogbuagu, UNICAL graduate leading COVID-19 vaccine research in US". TheCable. 2020-11-22. Retrieved 2022-02-02.
  19. ↑ Barakat, Lydia Aoun; Dunne, Dana W.; Tetrault, Jeanette M.; Soares, Sarita; Chia, David; Ogbuagu, Onyema E.; Moriarty, John P.; Huot, Stephen J.; Green, Michael L. (November 2018). "The Changing Face of HIV Care: Expanding HIV Training in an Internal Medicine Residency Program". Academic Medicine: Journal of the Association of American Medical Colleges. 93 (11): 1673–1678. doi: 10.1097/ACM.0000000000002317 . ISSN   1938-808X. PMID   29901657. S2CID   49191395.
  20. ↑ "Yale physician, daughter share message about COVID vaccination as pediatric hospitalizations surge". WTNH.com. 2022-01-08. Retrieved 2022-02-03.
  21. ↑ Lucci-Canapari, Jeanna. "Vaccine Clinic Offers Choice and Reassurance to New Haven Children". medicine.yale.edu. Retrieved 2022-02-03.
  22. ↑ Parmar, Reema (2020-05-12). "Research by Young ISN Members Highlights the Importance of Sub-tertiary Hospital Capacity to Manage Kidney Disease in Low- and Middle-income Countries". International Society of Nephrology. Retrieved 2022-02-03.
  23. ↑ Horowitch, Rose (2020-04-06). "Yale investigates potential treatments for COVID-19". Yale Daily News. Retrieved 2021-06-17.
  24. ↑ "Onyema E. Ogbuagu, MD Infectious Disease of Yale New Haven Hospital". www.ynhh.org. Retrieved 2022-02-02.
  25. ↑ "Onyema Ogbuagu". Yale Medicine. Retrieved 2021-06-17.
  26. ↑ Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Arribas López, José Ramón; Cattelan, Anna Maria; Soriano Viladomiu, Alex; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann (2020-09-15). "Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial". JAMA. 324 (11): 1048–1057. doi:10.1001/jama.2020.16349. ISSN   1538-3598. PMC   7442954 . PMID   32821939.
  27. ↑ Nneji, Bernard (April 29, 2021). "COVID-19 Clinical Trials for Treatment and Prevention - Learning from Successes". Columbia Alumni Association of Fairfield County. Retrieved 2022-02-02.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.